<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35460510</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1865-8652</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Advances in therapy</Title>
          <ISOAbbreviation>Adv Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Disease Progression Stages and Burden in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Supplemented by Electronic Medical Records.</ArticleTitle>
        <Pagination>
          <StartPage>2906</StartPage>
          <EndPage>2919</EndPage>
          <MedlinePgn>2906-2919</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-022-02117-1</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">This study aims to identify stages of Duchenne muscular dystrophy (DMD) and assess the disease burden by progression stage using real-world administrative claims supplemented by relevant electronic medical record (EMR) data.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Claims and EMR data from the Decision Resources Group's Real World Data Repository (2011-2020) were used to identify patients with DMD by diagnosis code and to stratify them into four disease stages by diagnosis and procedure markers reflective of DMD progression. Clinical and medical history data from the Cooperative International Neuromuscular Research Group (CINRG) were used to validate the developed claims-based staging algorithm. The distribution and drivers by disease stage, as well as disease burden, were examined.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 938 (94%) of patients with DMD identified in claims/EMR data had sufficient information for stage classification. Patients were classified by stage based on patient characteristics and the presence or absence of progression markers such as genetic testing, wheelchair usage, scoliosis treatment, or ventilation assistance. Average ages at stages 1-4 are 7, 13, 18, and 23 years, respectively. Using natural history data, the claims-based staging algorithm was validated with high sensitivity and specificity rates. Both healthcare resource utilization and medical charges increased by stage. For example, the average annualized total charges were $17,688 (stage 1), $36,868 (stage 2), $72,801 (stage 3), and $167,285 (stage 4).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Large-scale claims data supplemented by EMR data can be used to characterize DMD progression and evaluate disease burden which may inform the design of future real-world studies about DMD.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Iff</LastName>
            <ForeName>Joel</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Sarepta Therapeutics, Inc, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0001-6246-2292</Identifier>
            <AffiliationInfo>
              <Affiliation>Analysis Group, Inc., 1010 El Camino Real #310, Menlo Park, CA, 94025, USA. Yi.Zhong@analysisgroup.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gupta</LastName>
            <ForeName>Deepshekhar</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis Group, Inc., 1010 El Camino Real #310, Menlo Park, CA, 94025, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paul</LastName>
            <ForeName>Xander</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis Group, Inc., 1010 El Camino Real #310, Menlo Park, CA, 94025, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tuttle</LastName>
            <ForeName>Edward</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis Group, Inc., 1010 El Camino Real #310, Menlo Park, CA, 94025, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Henricson</LastName>
            <ForeName>Erik</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>UC Davis Medical Center, Sacramento, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schrader</LastName>
            <ForeName>Rachel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Parent Project Muscular Dystrophy, Hackensack, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>CINRG DNHS Investigators</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Adv Ther</MedlineTA>
        <NlmUniqueID>8611864</NlmUniqueID>
        <ISSNLinking>0741-238X</ISSNLinking>
      </MedlineJournalInfo>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020388" MajorTopicYN="Y">Muscular Dystrophy, Duchenne</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012600" MajorTopicYN="Y">Scoliosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Disease burden</Keyword>
        <Keyword MajorTopicYN="N">Disease stages</Keyword>
        <Keyword MajorTopicYN="N">Duchenne muscular dystrophy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>12</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35460510</ArticleId>
        <ArticleId IdType="doi">10.1007/s12325-022-02117-1</ArticleId>
        <ArticleId IdType="pii">10.1007/s12325-022-02117-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-021-00248-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Zaidy SA, Lloyd-Puryear M, Kennedy A, Lopez V, Mendell JR. A roadmap to newborn screening for Duchenne muscular dystrophy. Int J Neonatal Screen. 2017;3(2):8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijns3020008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connolly AM, Zaidman CM, Golumbek PT, et al. Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy. Muscle Nerve. 2019;59(6):650–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.26441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spehrs-Ciaffi V, Fitting JW, Cotting J, Jeannet PY. Respiratory surveillance of patients with Duchenne and Becker muscular dystrophy. J Pediatr Rehabil Med. 2009;2(2):115–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/PRM-2009-0071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landfeldt E, Lindgren P, Bell CF, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schreiber-Katz O, Klug C, Thiele S, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9:210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13023-014-0210-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PTC Therapeutics. 2014 PTC Therapeutics receives conditional approval in the European Union for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy. http://ir.ptcbio.com/releasedetail.cfm?releaseid=863914 . Accessed 6 Mar 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>US Food and Drug Administration. FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation . Accessed 6 Mar 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Sheehan DW, Birnkrant DJ, Benditt JO, et al. Respiratory management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018;142(Suppl 2):S62–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2018-0333H</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Case LE, Apkon SD, Eagle M, et al. Rehabilitation management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018;142(Suppl 2):S17–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2018-0333D</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koeks Z, Bladen CL, Salgado D, et al. Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database. J Neuromuscul Dis. 2017;4(4):293–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JND-170280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujino H, Iwata Y, Saito T, Matsumura T, Fujimura H, Imura O. The experiences of patients with Duchenne muscular dystrophy in facing and learning about their clinical conditions. Int J Qual Stud Health Well-being. 2016;11:32045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3402/qhw.v11.32045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muntoni F, Domingos J, Manzur AY, et al. Categorising trajectories and individual item changes of the North Star ambulatory assessment in patients with Duchenne muscular dystrophy. PLoS One. 2019;14(9):e0221097.</Citation>
        </Reference>
        <Reference>
          <Citation>Goemans N, Wong B, Van den Hauwe M, et al. Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: a multi-institutional collaboration. PLoS One. 2020;15(6):e0232870.</Citation>
        </Reference>
        <Reference>
          <Citation>Goemans N, Signorovitch J, Sajeev G, et al. Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. Neurology. 2020;95(10):e1381–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000010170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong BL. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center. J Comp Eff Res. 2020;9(3):177–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/cer-2019-0170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000;23(9):1344–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-4598(200009)23:9&lt;1344::AID-MUS4&gt;3.0.CO;2-F</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000003217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bello L, Gordish-Dressman H, Morgenroth LP, et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study. Neurology. 2015;85(12):1048–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(17)32160-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald CM, Henricson EK, Abresch RT, et al. The Cooperative International Neuromuscular Research Group Duchenne natural history study–a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve. 2013;48(1):32–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.23807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Medicare &amp; Medicaid Services. 2021 ICD-10-CM. https://www.cms.gov/medicare/icd-10/2021-icd-10-cm . Accessed 6 Mar 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Landfeldt E, Alfredsson L, Straub V, Lochmuller H, Bushby K, Lindgren P. Economic evaluation in Duchenne muscular dystrophy: model frameworks for cost-effectiveness analysis. Pharmacoeconomics. 2017;35(2):249–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40273-016-0461-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao KP, Cai T, Gainer V, et al. Electronic medical records for discovery research in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010;62(8):1120–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.20184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirelman A, Ben Or Frank M, Melamed M, et al. Detecting sensitive mobility features for Parkinson's disease stages via machine learning. Mov Disord. 2021;36(9):2144–55.</Citation>
        </Reference>
        <Reference>
          <Citation>Benchimol EI, Guttmann A, Mack DR, et al. Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario. Canada J Clin Epidemiol. 2014;67(8):887–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jclinepi.2014.02.019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. Am J Med Qual. 1999;14(6):270–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/106286069901400607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teoh LJ, Geelhoed EA, Bayley K, Leonard H, Laing NG. Health care utilization and costs for children and adults with Duchenne muscular dystrophy. Muscle Nerve. 2016;53(6):877–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.24965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Spec Pharm. 2017;23(6):633–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28530521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stott-Miller M, Vlahiotis A, Palmer L. Treatment patterns, resource utilization and costs in muscular dystrophy patients: analysis using administrative claims data (Abstract). Value Health. 2015;18(7):PA764-A5.</Citation>
        </Reference>
        <Reference>
          <Citation>Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13023-017-0631-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayer O, Karafilidis J, Higgins K, Griffin B. Descriptive characteristics of males with Duchenne muscular dystrophy using insurance claims data. Neuromuscul Disord. 2018;28(S2):S39.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
